594 related articles for article (PubMed ID: 15947080)
21. Natalizumab for relapsing multiple sclerosis.
Jeffery DR
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
[No Abstract] [Full Text] [Related]
22. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
23. [Progressive multifocal leukoencephalopathy].
Pál E; Aschermann Z; Gömöri E; Kovács GG; Simon G; Maródi L; Komoly S; Illés Z
Ideggyogy Sz; 2007 May; 60(5-6):263-8. PubMed ID: 17578275
[TBL] [Abstract][Full Text] [Related]
24. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
26. Natalizumab for relapsing multiple sclerosis.
Meyer MA
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
[No Abstract] [Full Text] [Related]
27. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
28. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
29. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
30. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
31. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
32. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
33. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy.
McGuire D; Barhite S; Hollander H; Miles M
Ann Neurol; 1995 Mar; 37(3):395-9. PubMed ID: 7695239
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
35. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
[TBL] [Abstract][Full Text] [Related]
37. JC virus DNA in healthy brain tissue: a challenge for progressive multifocal leukoencephalopathy diagnosis.
Focosi D; Kast RE; Maggi F; Ceccherini-Nelli L; Petrini M
Ann Neurol; 2009 Feb; 65(2):230; author reply 230-31. PubMed ID: 19259969
[No Abstract] [Full Text] [Related]
38. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy.
Sabath BF; Major EO
J Infect Dis; 2002 Dec; 186 Suppl 2():S180-6. PubMed ID: 12424695
[TBL] [Abstract][Full Text] [Related]
39. Progressive multifocal leukoencephalopathy: clinical description and demonstration of the causal agent.
Carrada-Bravo T
Neurologia; 2005 Oct; 20(8):422-5. PubMed ID: 16220408
[TBL] [Abstract][Full Text] [Related]
40. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
